Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond

Pharmacology and Therapeutics

Volumn 129, Issue 3, 2011, Pages 267-289

  Xie, Hong Guang ^a   Zou, Jian Jun ^a   Hu, Zuo Ying ^a   Zhang, Jun Jie ^a   Ye, Fei ^a   Chen, Shao Liang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; Aspirin; Clopidogrel; CYP2C19; CYP3A4; Percutaneous coronary intervention; Platelet; Stent; Stent thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PROTON PUMP INHIBITOR; SARTAN DERIVATIVE; UNCLASSIFIED DRUG; WARFARIN;

AGE; ARTICLE; BLEEDING; BODY WEIGHT; COMORBIDITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG METABOLISM; DRUG RESPONSE; ETHNICITY; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAPEFRUIT JUICE; HUMAN; INTRACELLULAR SIGNALING; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; NONHUMAN; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; THROMBOCYTE FUNCTION;

EID: 79651472053     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.10.001     Document Type: Review

References (287)

1. D.R. Abernethy Grapefruits and drugs: When is statistically significant clinically significant? J Clin Invest 99 1997 2297 2298
2. A. Adedoyin, P.A. Arns, W.O. Richards, G.R. Wilkinson, and R.A. Branch Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6 Clin Pharmacol Ther 64 1998 8 17
3. V. Afshar-Kharghan, C.Q. Li, M. Khoshnevis-Asl, and J.A. Lopez Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex Blood 94 1999 186 191
4. N. Ajzenberg, C. Berroeta, I. Philip, B. Grandchamp, P. Ducellier, and V. Huart Association of the -92C/G and 807C/T polymorphisms of the alpha2 subunit gene with human platelets alpha2beta1 receptor density Arterioscler Thromb Vasc Biol 25 2005 1756 1760
5. B. Aleil, C. Leon, J.P. Cazenave, and C. Gachet CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: Implications for its monitoring J Thromb Haemost 7 2009 1747 1749
6. M.M. Ameyaw, F. Regateiro, T. Li, X. Liu, M. Tariq, and A. Mobarek MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity Pharmacogenetics 11 2001 217 221
7. J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, and D.E. Casey Jr. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
8. D.J. Angiolillo, and F. Alfonso Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure Thromb Haemost 98 2007 707 709
9. D.J. Angiolillo, E. Bernardo, J. Palazuelos, B. Desai, I. Weisberg, and F. Alfonso Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study Thromb Haemost 99 2008 161 168
10. D.J. Angiolillo, E. Bernardo, C. Ramirez, M.A. Costa, M. Sabate, and P. Jimenez-Quevedo Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 48 2006 298 304
11. D.J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M.A. Costa, and J. Palazuelos Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547
12. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
13. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, M. Sabate, and C. Fernandez PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation Blood Coagul Fibrinolysis 15 2004 89 93
14. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, C. Barrera-Ramirez, and M. Sabate Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting Thromb Res 115 2005 101 108
15. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, U. Cavallari, and E. Trabetti Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900
16. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, U. Cavallari, and E. Trabetti Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease Thromb Res 116 2005 491 497
17. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, J. Escaned, and R. Moreno 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment Blood Coagul Fibrinolysis 15 2004 427 433
18. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, and C. Banuelos High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability Eur Heart J 25 2004 1903 1910
19. Anonymous FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm 2010
20. Anonymous Grapefruit-drug interactions Available: http://www. powernetdesign.com/grapefruit/ 2010
21. Anonymous Plavix prescribing information http://products.sanofi-aventis. us/plavix/plavix.html 2010
22. E.M. Antman, M. Hand, P.W. Armstrong, E.R. Bates, L.A. Green, and L.K. Halasyamani 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee Circulation 117 2008 296 329
23. E.M. Antman, M. Hand, P.W. Armstrong, E.R. Bates, L.A. Green, and L.K. Halasyamani 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 2008 210 247
24. T. Aoyama, S. Yamano, D.J. Waxman, D.P. Lapenson, U.A. Meyer, and V. Fischer Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine J Biol Chem 264 1989 10388 10395
25. P. Artursson, and J. Karlsson Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem Biophys Res Commun 175 1991 880 885
26. P. Aukrust, B. Halvorsen, T. Ueland, A.E. Michelsen, M. Skjelland, and L. Gullestad Activated platelets and atherosclerosis Expert Rev Cardiovasc Ther 8 2010 1297 1307
27. S.P. Ayalasomayajula, S. Vaidyanathan, C. Kemp, P. Prasad, A. Balch, and W.P. Dole Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin J Clin Pharmacol 47 2007 613 619
28. D.G. Bailey, and G.K. Dresser Interactions between grapefruit juice and cardiovascular drugs Am J Cardiovasc Drugs 4 2004 281 297
29. C. Balram, A. Sharma, C. Sivathasan, and E.J. Lee Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: Phenotypic-genotypic correlates Br J Clin Pharmacol 56 2003 78 83
30. T. Bauer, A.K. Gitt, C. Junger, R. Zahn, O. Koeth, and F. Towae Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: Predictors and outcomes of nonadherence Eur J Cardiovasc Prev Rehabil 17 2010 576 581
31. L. Bergandi, M. Cordero, M. Anselmino, G. Ferraro, L. Ravera, and P. Dalmasso Altered nitric oxide/cGMP platelet signaling pathway in platelets from patients with acute coronary syndromes Clin Res Cardiol 99 2010 557 564
32. I. Bernlochner, S. Steinhubl, S. Braun, T. Morath, J. Jaitner, and J. Stegherr Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment Thromb Haemost 104 2010 1193 1200
33. M.E. Bertrand, H.J. Rupprecht, P. Urban, and A.H. Gershlick Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629
34. C. Bertrand-Thiebault, H. Berrahmoune, A. Thompson, B. Marie, S. Droesch, and G. Siest Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation Ann Hum Genet 72 2008 178 183
35. D.L. Bhatt What makes platelets angry: Diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy? J Am Coll Cardiol 52 2008 1060 1061
36. D.L. Bhatt Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit? JAMA 302 2009 896 897
37. D.L. Bhatt, J. Scheiman, N.S. Abraham, E.M. Antman, F.K. Chan, and C.D. Furberg ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Circulation 118 2008 1894 1909
38. K.P. Bliden, J. DiChiara, U.S. Tantry, A.K. Bassi, S.K. Chaganti, and P.A. Gurbel Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 49 2007 657 666
39. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, and O. Wittenberg Adjusted clopidogrel loading doses according to vasodilator- stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
40. N. Bonello-Palot, S. Armero, F. Paganelli, J. Mancini, A. De Labriolle, and C. Bonello Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention Am J Cardiol 104 2009 1511 1515
41. H.J. Bouman, J.W. van Werkum, G. Rudez, F.W. Leebeek, A. Kruit, and C.M. Hackeng The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor Thromb Haemost 103 2010 379 386
42. M.L. Brackbill, R.S. Kidd, A.D. Abdoo, J.G. Warner Jr., and A.F. Harralson Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome Heart Vessels 24 2009 73 78
43. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, and C.S. Ernest Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
44. J.T. Brandt, C.D. Payne, S.D. Wiviott, G. Weerakkody, N.A. Farid, and D.S. Small A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e9-66.e16
45. P. Buonamici, R. Marcucci, A. Migliorini, G.F. Gensini, A. Santini, and R. Paniccia Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317
46. H. Caplain, F. Donat, C. Gaud, and J. Necciari Pharmacokinetics of clopidogrel Semin Thromb Hemost 25 Suppl 2 1999 25 28
47. H. Caplain, J.J. Thebault, and J. Necciari Clopidogrel does not affect the pharmacokinetics of theophylline Semin Thromb Hemost 25 Suppl 2 1999 65 68
48. CAPRIE Steering Committee A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE) Lancet 348 1996 1329 1339
49. M. Cattaneo, M.L. Zighetti, R. Lombardi, C. Martinez, A. Lecchi, and P.B. Conley Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding Proc Natl Acad Sci USA 100 2003 1978 1983
50. B.L. Chen, Y. Chen, J.H. Tu, Y.L. Li, W. Zhang, and Q. Li Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms J Clin Pharmacol 49 2009 574 581
51. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, and R. Peto Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial Lancet 366 2005 1607 1621
52. M. Chen, L. Ma, G.L. Drusano, J.S. Bertino Jr., and A.N. Nafziger Sex differences in CYP3A activity using intravenous and oral midazolam Clin Pharmacol Ther 80 2006 531 538
53. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
54. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2 C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study Lancet 373 2009 309 317
55. J.P. Collet, J. Silvain, A. Landivier, M.L. Tanguy, G. Cayla, and A. Bellemain Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: The Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study Circulation 118 2008 1225 1233
56. S.D. Collins, R. Torguson, M.A. Gaglia Jr., G. Lemesle, A.I. Syed, and I. Ben Dor Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 122 2010 1085 1090
57. S.J. Connolly, J. Pogue, R.G. Hart, S.H. Hohnloser, M. Pfeffer, and S. Chrolavicius Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
58. T. Cuisset, C. Frere, J. Quilici, F. Barbou, P.E. Morange, and T. Hovasse High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
59. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, L. Nait-Saidi, and J. Carvajal Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting J Am Coll Cardiol 48 2006 1339 1345
60. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, N. Saut, and M. Lambert Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome Thromb Res 120 2007 893 899
61. F. d'Esposito, N. Nebot, R.J. Edwards, and M. Murray Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease Br J Clin Pharmacol 70 2010 400 408
62. G. Davi, M.T. Guagnano, G. Ciabattoni, S. Basili, A. Falco, and M. Marinopiccoli Platelet activation in obese women: Role of inflammation and oxidant stress JAMA 288 2002 2008 2014
63. G. Davi, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
64. M. Debrunner, E. Schuiki, E. Minder, E. Straumann, B. Naegeli, and R. Mury Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock Clin Res Cardiol 97 2008 298 305
65. J.A. Delaney, L. Opatrny, J.M. Brophy, and S. Suissa Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding CMAJ 177 2007 347 351
66. Z. Ding, S. Kim, R.T. Dorsam, J. Jin, and S.P. Kunapuli Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270 Blood 101 2003 3908 3914
67. R.T. Dorsam, and S.P. Kunapuli Central role of the P2Y12 receptor in platelet activation J Clin Invest 113 2004 340 345
68. C. Dumaual, X. Miao, T.M. Daly, C. Bruckner, R. Njau, and D.J. Fu Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System Pharmacogenomics 8 2007 293 305
69. D. Erlinge, C. Varenhorst, O.O. Braun, S. James, K.J. Winters, and J.A. Jakubowski Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo J Am Coll Cardiol 52 2008 1968 1977
70. N.A. Farid, C.D. Payne, D.S. Small, K.J. Winters, C.S. Ernest, and J.T. Brandt Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently Clin Pharmacol Ther 81 2007 735 741
71. C. Fatini, E. Sticchi, P. Bolli, R. Marcucci, B. Giusti, and R. Paniccia eNOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment Platelets 20 2009 548 554
72. G. Feher, K. Koltai, B. Alkonyi, E. Papp, Z. Keszthelyi, and G. Kesmarky Clopidogrel resistance: Role of body mass and concomitant medications Int J Cardiol 120 2007 188 192
73. F. Feit, M.D. Voeltz, M.J. Attubato, A.M. Lincoff, D.P. Chew, and J.A. Bittl Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial Am J Cardiol 100 2007 1364 1369
74. R. Feliste, D. Delebassee, M.F. Simon, H. Chap, G. Defreyn, and E. Vallee Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP Thromb Res 48 1987 403 415
75. S. Fichtlscherer, S. Dimmeler, S. Breuer, R. Busse, A.M. Zeiher, and I. Fleming Inhibition of cytochrome P450 2 C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease Circulation 109 2004 178 183
76. V.H. Flood, J.C. Gill, P.A. Morateck, P.A. Christopherson, K.D. Friedman, and S.L. Haberichter Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor Blood 116 2010 280 286
77. P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-Loza, J.L. Reny, and M. Aiach Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 2003 989 995
78. P. Fontana, J.S. Hulot, P. De Moerloose, and P. Gaussem Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects J Thromb Haemost 5 2007 2153 2155
79. P. Fontana, D. Senouf, and F. Mach Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2 C19*2 allele on clopidogrel responsiveness Thromb Res 121 2008 463 468
80. C. Frere, T. Cuisset, B. Gaborit, M.C. Alessi, and J.S. Hulot The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome J Thromb Haemost 7 2009 1409 1411
81. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
82. D.J. Friedman, M.E. Talbert, D.W. Bowden, B.I. Freedman, Y. Mukanya, and K. Enjyoji Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease Diabetes 58 2009 999 1006
83. T. Furuta, T. Iwaki, and K. Umemura Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes Br J Clin Pharmacol 70 2010 383 392
84. J. Geiger, J. Brich, P. Honig-Liedl, M. Eigenthaler, P. Schanzenbacher, and J.M. Herbert Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel Arterioscler Thromb Vasc Biol 19 1999 2007 2011
85. T. Geisler, D. Grass, B. Bigalke, K. Stellos, T. Drosch, and K. Dietz The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
86. T. Geisler, H. Langer, M. Wydymus, K. Gohring, C. Zurn, and B. Bigalke Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425
87. T. Geisler, E. Schaeffeler, J. Dippon, S. Winter, V. Buse, and C. Bischofs CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation Pharmacogenomics 9 2008 1251 1259
88. J. George, M. Murray, K. Byth, and G.C. Farrell Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease Hepatology 21 1995 120 128
89. M. Gilard, B. Arnaud, J.C. Cornily, G. Le Gal, K. Lacut, and G. Le Calvez Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
90. M. Gilard, B. Arnaud, G. Le Gal, J.F. Abgrall, and J. Boschat Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin J Thromb Haemost 4 2006 2508 2509
91. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Cytochrome P450 2 C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12 G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
92. B. Giusti, A.M. Gori, R. Marcucci, I. Sestini, C. Saracini, and R. Paniccia Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment Atherosclerosis 196 2008 341 348
93. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Relation of cytochrome P450 2 C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
94. O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, and A. Schomig Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting Eur Heart J 25 2004 1898 1902
95. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition Heart 96 2010 186 189
96. P.A. Gurbel, and R.D. Anderson New concept in coronary angioplasty: Dilatation with a helical balloon that allows simultaneous autoperfusion Cathet Cardiovasc Diagn 40 1997 109 116
97. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
98. P.A. Gurbel, K.P. Bliden, K.M. Hayes, J.A. Yoho, W.R. Herzog, and U.S. Tantry The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 45 2005 1392 1396
99. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
100. P.A. Gurbel, K.P. Bliden, W. Samara, J.A. Yoho, K. Hayes, and M.Z. Fissha Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study J Am Coll Cardiol 46 2005 1827 1832
101. P.A. Gurbel, W.C. Lau, and U.S. Tantry Omeprazole: A possible new candidate influencing the antiplatelet effect of clopidogrel J Am Coll Cardiol 51 2008 261 263
102. P.A. Gurbel, and U.S. Tantry Drug insight: Clopidogrel nonresponsiveness Nat Clin Pract Cardiovasc Med 3 2006 387 395
103. P.A. Gurbel, U.S. Tantry, A.R. Shuldiner, and D.J. Kereiakes Genotyping: One Piece of the Puzzle to Personalize Antiplatelet Therapy J Am Coll Cardiol 56 2010 112 116
104. K. Hagihara, Y. Nishiya, A. Kurihara, M. Kazui, N.A. Farid, and T. Ikeda Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine Drug Metab Pharmacokinet 23 2008 412 420
105. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 2005 1685 1695
106. A. Harmsze, J.W. van Werkum, H.J. Bouman, H.J. Ruven, N.J. Breet, and J.M. ten Berg Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation Pharmacogenet Genomics 20 2010 18 25
107. A.M. Harmsze, K. Robijns, J.W. van Werkum, N.J. Breet, C.M. Hackeng, and J.M. ten Berg The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response Thromb Haemost 103 2010 920 925
108. A.M. Harmsze, J.W. van Werkum, J.M. ten Berg, C.M. Hackeng, and V.H. Deneer Concomitant use of sulfonylurea antidiabetics attenuates on-clopidogrel platelet reactivity. (Abstract) Circulation 120 2009 S501
109. A.M. Harmsze, J.W. van Werkum, J.M. ten Berg, B. Zwart, H.J. Bouman, and N.J. Breet CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: A case-control study Eur Heart J 31 2010 3046 3053
110. B. Hechler, Y. Zhang, A. Eckly, J.P. Cazenave, C. Gachet, and K. Ravid Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice J Thromb Haemost 1 2003 155 163
111. A.A. Heestermans, J.W. van Werkum, E. Schomig, J.M. ten Berg, and D. Taubert Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites J Thromb Haemost 4 2006 1143 1145
112. T.J. Helton, A.A. Bavry, D.J. Kumbhani, S. Duggal, H. Roukoz, and D.L. Bhatt Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: A meta-analysis of randomized trials Am J Cardiovasc Drugs 7 2007 289 297
113. J.M. Herbert, and P. Savi P2Y12, a new platelet ADP receptor, target of clopidogrel Semin Vasc Med 3 2003 113 122
114. A.J. Hermosillo, and S.A. Spinler Aspirin, clopidogrel, and warfarin: Is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother 42 2008 790 805
115. S.L. Hetherington, R.K. Singh, D. Lodwick, J.R. Thompson, A.H. Goodall, and N.J. Samani Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP Arterioscler Thromb Vasc Biol 25 2005 252 257
116. B.I. Hirschowitz, and C.J. Hawkey Questions regarding future research on aspirin and the gastrointestinal tract Am J Med 110 2001 74S 78S
117. J. Hirsh, J.E. Dalen, V. Fuster, L.B. Harker, C. Patrono, and G. Roth Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects Chest 108 1995 247S 257S
118. P.M. Ho, T.M. Maddox, L. Wang, S.D. Fihn, R.L. Jesse, and E.D. Peterson Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
119. W. Hochholzer, D. Trenk, H.P. Bestehorn, B. Fischer, C.M. Valina, and M. Ferenc Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750
120. W. Hochholzer, D. Trenk, M.F. Fromm, C.M. Valina, C. Stratz, and H.P. Bestehorn Impact of cytochrome P450 2 C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
121. W. Hochholzer, D. Trenk, D. Frundi, P. Blanke, B. Fischer, and K. Andris Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564
122. G. Hollopeter, H.M. Jantzen, D. Vincent, G. Li, L. England, and V. Ramakrishnan Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202 207
123. D.R. Holmes Jr., G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning". A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Circulation 122 2010 537 557
124. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2 C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
125. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, and O. Barthelemy Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
126. M. Humbert, P. Nurden, C. Bihour, J.M. Pasquet, J. Winckler, and E. Heilmann Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation Arterioscler Thromb Vasc Biol 16 1996 1532 1543
127. R. Iijima, G. Ndrepepa, J. Mehilli, R.A. Byrne, S. Schulz, and F.J. Neumann Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention Eur Heart J 30 2009 290 296
128. F. Ishida, K. Furihata, K. Ishida, J. Yan, K. Kitano, and K. Kiyosawa The largest variant of platelet glycoprotein Ib alpha has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine145 Blood 86 1995 1357 1360
129. A.K. Jacobson Platelet ADP receptor antagonists: Ticlopidine and clopidogrel Best Pract Res Clin Haematol 17 2004 55 64
130. R.C. Jin, B. Voetsch, and J. Loscalzo Endogenous mechanisms of inhibition of platelet function Microcirculation 12 2005 247 258
131. T. Jinnai, H. Horiuchi, T. Makiyama, J. Tazaki, T. Tada, and M. Akao Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan Circ J 73 2009 1498 1503
132. A.D. Johnson, L.R. Yanek, M.H. Chen, N. Faraday, M.G. Larson, and G. Tofler Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists Nat Genet 42 2010 608 613
133. C.I. Jones, S. Bray, S.F. Garner, J. Stephens, B. de Bono, and W.G. Angenent A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways Blood 114 2009 1405 1416
134. D.N. Juurlink, T. Gomes, D.T. Ko, P.E. Szmitko, P.C. Austin, and J.V. Tu A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
135. M.K. Kang, Y.H. Jeong, S.E. Yoon, J.S. Koh, I.S. Kim, and Y. Park Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention J Atheroscler Thromb 17 2010 1122 1131
136. A. Kastrati, N. von Beckerath, A. Joost, G. Pogatsa-Murray, O. Gorchakova, and A. Schomig Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy Circulation 110 2004 1916 1919
137. M. Kazui, Y. Nishiya, T. Ishizuka, K. Hagihara, N.A. Farid, and O. Okazaki Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
138. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of CYP2C19
139. K.A. Kim, P.W. Park, and J.Y. Park Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects Eur J Clin Pharmacol 64 2008 589 597
140. R.B. Kim, B.F. Leake, E.F. Choo, G.K. Dresser, S.V. Kubba, and U.I. Schwarz Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2001 189 199
141. M. Kimura, I. Ieiri, Y. Wada, K. Mamiya, A. Urae, and E. Iimori Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: Possible effect of age, liver disease and length of therapy Br J Clin Pharmacol 47 1999 115 119
142. S.B. King III, S.C. Smith Jr., J.W. Hirshfeld Jr., A.K. Jacobs, D.A. Morrison, and D.O. Williams 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation 117 2008 261 295
143. T.D. Kinnaird, E. Stabile, G.S. Mintz, C.W. Lee, D.A. Canos, and N. Gevorkian Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 2003 930 935
144. M. Kotlyar, and S.W. Carson Effects of obesity on the cytochrome P450 enzyme system Int J Clin Pharmacol Ther 37 1999 8 19
145. R.W. Kuijpers, N.M. Faber, H.T. Cuypers, W.H. Ouwehand, and A.E. dem Borne NH2-terminal globular domain of human platelet glycoprotein Ib alpha has a methionine 145/threonine145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens J Clin Invest 89 1992 381 384
146. S. Kulkarni, S.M. Dopheide, C.L. Yap, C. Ravanat, M. Freund, and P. Mangin A revised model of platelet aggregation J Clin Invest 105 2000 783 791
147. T.J. Kunicki, M. Kritzik, D.S. Annis, and D.J. Nugent Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence Blood 89 1997 1939 1943
148. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, and A.S. Hopp Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction Circulation 107 2003 32 37 (Pubitemid 36070929)
149. W.C. Lau, T.D. Welch, T.A. Shields, M. Rubenfire, and P.A. Gurbel The effect of St. John's Wort on the pharmacodynamic efficacy of clopidogrel in hyporesponsive volunteers and patients. (A171) J Am Coll Cardiol 55 2010 E1600 E1602
150. J.M. Lee, S. Park, D.J. Shin, D. Choi, C.Y. Shim, and Y.G. Ko Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans Am J Cardiol 104 2009 46 51
151. H.P. Lei, X.Y. Yu, H.T. Xie, H.H. Li, L. Fan, and L.L. Dai Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers Xenobiotica 40 2010 275 281
152. E.I. Lev, R.T. Patel, S. Guthikonda, D. Lopez, P.F. Bray, and N.S. Kleiman Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel Thromb Res 119 2007 355 360
153. X.Q. Li, T.B. Andersson, M. Ahlstrom, and L. Weidolf Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities Drug Metab Dispos 32 2004 821 827
154. R. Lins, J. Broekhuysen, J. Necciari, and X. Deroubaix Pharmacokinetic profile of 14 C-labeled clopidogrel Semin Thromb Hemost 25 Suppl 2 1999 29 33
155. Y.T. Liu, H.P. Hao, C.X. Liu, G.J. Wang, and H.G. Xie Drugs as CYP3A probes, inducers, and inhibitors Drug Metab Rev 39 2007 699 721
156. J.A. Lopez, E.H. Ludwig, and B.J. McCarthy Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region. Structure/function implications J Biol Chem 267 1992 10055 10061
157. A. Lotfi, M.J. Schweiger, G.R. Giugliano, S.A. Murphy, and C.P. Cannon High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis Am Heart J 155 2008 954 958
158. M. Lotrionte, G.G. Biondi-Zoccai, P. Agostoni, A. Abbate, D.J. Angiolillo, and M. Valgimigli Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Am J Cardiol 100 2007 1199 1206
159. K.S. Lown, D.G. Bailey, R.J. Fontana, S.K. Janardan, C.H. Adair, and L.A. Fortlage Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression J Clin Invest 99 1997 2545 2553
160. L.A. Malek, B. Kisiel, M. Spiewak, M. Grabowski, K.J. Filipiak, and G. Kostrzewa Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel Circ J 72 2008 1165 1169
161. H. Mani, S.W. Toennes, B. Linnemann, D.A. Urbanek, J. Schwonberg, and G.F. Kauert Determination of clopidogrel main metabolite in plasma: A useful tool for monitoring therapy? Ther Drug Monit 30 2008 84 89
162. A.J. Marcus, M.J. Broekman, J.H. Drosopoulos, N. Islam, T.N. Alyonycheva, and L.B. Safier The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39 J Clin Invest 99 1997 1351 1360
163. A.J. Marcus, M.J. Broekman, J.H. Drosopoulos, N. Islam, D.J. Pinsky, and C. Sesti Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: Implications for ischemic vascular diseases J Pharmacol Exp Ther 305 2003 9 16
164. A.J. Marcus, L.B. Safier, K.A. Hajjar, H.L. Ullman, N. Islam, and M.J. Broekman Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells J Clin Invest 88 1991 1690 1696
165. C. Marzolini, E. Paus, T. Buclin, and R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
166. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
167. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
168. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
169. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis Lancet 376 2010 1312 1319
170. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study Lancet 358 2001 527 533
171. A.D. Michelson, M.D. Linden, M.I. Furman, Y. Li, M.R. Barnard, and M.L. Fox Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance' J Thromb Haemost 5 2007 75 81
172. J.V. Mitsios, A.I. Papathanasiou, F.I. Rodis, M. Elisaf, J.A. Goudevenos, and A.D. Tselepis Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes Circulation 109 2004 1335 1338
173. J.E. Mobley, S.J. Bresee, D.C. Wortham, R.M. Craft, C.C. Snider, and R.C. Carroll Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization Am J Cardiol 93 2004 456 458
174. M. Mockel, R. Muller, J.O. Vollert, C. Muller, O. Danne, and R. Gareis Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: A multi-marker approach: The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II) Clin Res Cardiol 96 2007 604 612
175. G. Montalescot, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, and P.G. Steg A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938
176. R. Mullangi, and N.R. Srinivas Clopidogrel: Review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies Biomed Chromatogr 23 2009 26 41
177. K. Muller, S. Aichele, M. Herkommer, B. Bigalke, K. Stellos, and P. Htun Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease Atherosclerosis 213 2010 256 262
178. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg, and M. Gawaz Effects of statins on platelet inhibition by a high loading dose of clopidogrel Circulation 108 2003 2195 2197
179. I. Muller, F. Besta, C. Schulz, S. Massberg, A. Schonig, and M. Gawaz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb Haemost 89 2003 783 787
180. I. Muller, M. Seyfarth, S. Rudiger, B. Wolf, G. Pogatsa-Murray, and A. Schomig Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 2001 92 93 (Pubitemid 32973418)
181. T. Nakamura, T. Sakaeda, N. Ohmoto, T. Tamura, N. Aoyama, and T. Shirakawa Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas Drug Metab Dispos 30 2002 4 6
182. H. Neubauer, B. Gunesdogan, C. Hanefeld, M. Spiecker, and A. Mugge Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study Eur Heart J 24 2003 1744 1749
183. T.A. Nguyen, J.G. Diodati, and C. Pharand Resistance to clopidogrel: A review of the evidence J Am Coll Cardiol 45 2005 1157 1164
184. R.V. Nirogi, V.N. Kandikere, and K. Mudigonda Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects Arzneimittelforschung 56 2006 735 739
185. Y. Nishiya, K. Hagihara, T. Ito, M. Tajima, S. Miura, and A. Kurihara Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel Drug Metab Dispos 37 2009 589 593
186. Y. Nishiya, K. Hagihara, A. Kurihara, N. Okudaira, N.A. Farid, and O. Okazaki Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel Xenobiotica 39 2009 836 843
187. C.J. O'Donnell, M.G. Larson, D. Feng, P.A. Sutherland, K. Lindpaintner, and R.H. Myers Genetic and environmental contributions to platelet aggregation: The Framingham heart study Circulation 103 2001 3051 3056
188. M. O'Donoghue, and S.D. Wiviott Clopidogrel response variability and future therapies: Clopidogrel: Does one size fit all? Circulation 114 2006 e600 e606
189. Pare, G., Mehta, S. R., Yusuf, S., Anand, S. S., Connolly, S. J., Hirsh, J. et al. (2010). Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med 363, 1704-1714.
190. C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, and B. Charbonnier Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology Eur Heart J 25 2004 166 181
191. C. Patrono, B. Coller, G.A. FitzGerald, J. Hirsh, and G. Roth Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 234S 264S
192. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
193. G. Patti, G. Colonna, V. Pasceri, L.L. Pepe, A. Montinaro, and G. Di Sciascio Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Circulation 111 2005 2099 2106
194. P.A. Peeters, H.J. Crijns, W.J. Tamminga, J.H. Jonkman, J.P. Dickinson, and J. Necciari Clopidogrel, a novel antiplatelet agent, and digoxin: Absence of pharmacodynamic and pharmacokinetic interaction Semin Thromb Hemost 25 Suppl 2 1999 51 54
195. A. Pena, J.P. Collet, J.S. Hulot, J. Silvain, O. Barthelemy, and F. Beygui Can we override clopidogrel resistance? Circulation 119 2009 2854 2857
196. J.M. Pereillo, M. Maftouh, A. Andrieu, M.F. Uzabiaga, O. Fedeli, and P. Savi Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 30 2002 1288 1295
197. R.J. Peters, S.R. Mehta, K.A. Fox, F. Zhao, B.S. Lewis, and S.L. Kopecky Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 2003 1682 1687
198. J.L. Petersen, J.P. Dery, M.C. Fischi, A.F. Hernandez, P.M. Hranitzky, and S.V. Rao Highlights from the American College of Cardiology Annual Scientific Sessions 2003: March 28 to April 2, 2003 Am Heart J 146 2003 19 26
199. E. Piazuelo, J. Fuentes, M.A. Garcia-Gonzalez, P. Jimenez, and A. Lanas A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin Clin Ther 30 2008 121 130
200. P. Pignatelli, L. De Biase, L. Lenti, G. Tocci, A. Brunelli, and R. Cangemi Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure Blood 106 2005 1992 1994
201. M. Pirmohamed, S. James, S. Meakin, C. Green, A.K. Scott, and T.J. Walley Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients BMJ 329 2004 15 19 (Pubitemid 38869995)
202. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
203. M.J. Quinn, and D.J. Fitzgerald Ticlopidine and clopidogrel Circulation 100 1999 1667 1672
204. M. Ramsjo, E. Aklillu, L. Bohman, M. Ingelman-Sundberg, H.K. Roh, and L. Bertilsson CYP2C19 activity comparison between Swedes and Koreans: Effect of genotype, sex, oral contraceptive use, and smoking Eur J Clin Pharmacol 66 2010 871 877
205. W.A. Ray, K.T. Murray, M.R. Griffin, C.P. Chung, W.E. Smalley, and K. Hall Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: A cohort study Ann Intern Med 152 2010 337 345
206. M. Reist, M. Roy-de Vos, J.P. Montseny, J.M. Mayer, P.A. Carrupt, and Y. Berger Very slow chiral inversion of clopidogrel in rats: A pharmacokinetic and mechanistic investigation Drug Metab Dispos 28 2000 1405 1410
207. T. Richter, T.E. Murdter, G. Heinkele, J. Pleiss, S. Tatzel, and M. Schwab Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine J Pharmacol Exp Ther 308 2004 189 197
208. D.M. Roden, and A.R. Shuldiner Responding to the Clopidogrel Warning by the US Food and Drug Administration. Real Life Is Complicated Circulation 122 2010 445 448
209. D.M. Roden, and C.M. Stein Clopidogrel and the concept of high-risk pharmacokinetics Circulation 119 2009 2127 2130
210. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, and P. Theroux Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
211. J.E. Sadler Redeeming ristocetin Blood 116 2010 155 156
212. K. Sai, Y. Saito, N. Tatewaki, M. Hosokawa, N. Kaniwa, and T. Nishimaki-Mogami Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients Br J Clin Pharmacol 70 2010 222 233
213. K. Sangkuhl, T.E. Klein, and R.B. Altman Clopidogrel pathway Pharmacogenet Genomics 20 2010 463 465
214. P. Savi, J. Combalbert, C. Gaich, M.C. Rouchon, J.P. Maffrand, and Y. Berger The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A Thromb Haemost 72 1994 313 317
215. P. Savi, and J.M. Herbert Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin Thromb Hemost 31 2005 174 183
216. P. Savi, J.M. Herbert, A.M. Pflieger, F. Dol, D. Delebassee, and J. Combalbert Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel Biochem Pharmacol 44 1992 527 532
217. P. Savi, C. Labouret, N. Delesque, F. Guette, J. Lupker, and J.M. Herbert P2y(12), a new platelet ADP receptor, target of clopidogrel Biochem Biophys Res Commun 283 2001 379 383
218. P. Savi, M.C. Laplace, J.P. Maffrand, and J.M. Herbert Binding of [3 H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine J Pharmacol Exp Ther 269 1994 772 777
219. P. Savi, J.M. Pereillo, M.F. Uzabiaga, J. Combalbert, C. Picard, and J.P. Maffrand Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
220. J. Saw, D.M. Brennan, S.R. Steinhubl, D.L. Bhatt, K.H. Mak, and K. Fox Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial J Am Coll Cardiol 50 2007 291 295
221. J. Saw, S.R. Steinhubl, P.B. Berger, D.J. Kereiakes, V.L. Serebruany, and D. Brennan Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924
222. E. Schaeffeler, M. Eichelbaum, U. Brinkmann, A. Penger, S. Asante-Poku, and U.M. Zanger Frequency of C3435T polymorphism of MDR1 gene in African people Lancet 358 2001 383 384
223. A. Schomig Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N Engl J Med 361 2009 1108 1111
224. D. Schrenk, D. Brockmeier, K. Morike, K.W. Bock, and M. Eichelbaum A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers Eur J Clin Pharmacol 53 1998 361 367
225. W.S. Schroeder, L. Ghobrial, and P.J. Gandhi Possible mechanisms of drug-induced aspirin and clopidogrel resistance J Thromb Thrombolysis 22 2006 139 150
226. J.B. Schwartz The current state of knowledge on age, sex, and their interactions on clinical pharmacology Clin Pharmacol Ther 82 2007 87 96
227. V.L. Serebruany, M.G. Midei, A.I. Malinin, B.R. Oshrine, D.R. Lowry, and D.C. Sane Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study Arch Intern Med 164 2004 2051 2057
228. V.L. Serebruany, B.R. Oshrine, A.I. Malinin, D. Atar, A.D. Michelson, and J.J. Ferguson III Noncompliance in cardiovascular clinical trials Am Heart J 150 2005 882 886
229. H.J. Seyfarth, M. Koksch, G. Roethig, T. Rother, A. Neugebauer, and N. Klein Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation Am Heart J 143 2002 118 123
230. P.J. Sharis, C.P. Cannon, and J. Loscalzo The antiplatelet effects of ticlopidine and clopidogrel Ann Intern Med 129 1998 394 405
231. Y. Shimasaki, H. Yasue, M. Yoshimura, M. Nakayama, K. Kugiyama, and H. Ogawa Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction J Am Coll Cardiol 31 1998 1506 1510 (Pubitemid 28273291)
232. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2 C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
233. D. Sibbing, D. Gebhard, W. Koch, S. Braun, J. Stegherr, and T. Morath Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy J Thromb Haemost 8 2010 1685 1693
234. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2 C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
235. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, and K. Dorrler Cytochrome P450 2 C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
236. D. Sibbing, O. von Beckerath, A. Schomig, A. Kastrati, and N. von Beckerath P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel J Thromb Haemost 4 2006 912 914
237. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
238. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
239. D.S. Small, N.A. Farid, Y.G. Li, C.S. Ernest, C.D. Payne, and D.E. Salazar Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel Curr Med Res Opin 24 2008 2251 2257
240. D.S. Small, N.A. Farid, C.D. Payne, G.J. Weerakkody, Y.G. Li, and J.T. Brandt Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 2008 475 484
241. S.C. Smith Jr., T.E. Feldman, J.W. Hirshfeld Jr., A.K. Jacobs, M.J. Kern, and S.B. King III ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 113 2006 e166 e286
242. S.M. Smith, H.M. Judge, G. Peters, M. Armstrong, P. Fontana, and P. Gaussem Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy Platelets 17 2006 250 258
243. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, J.W. Jukema, and M.V. Huisman Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis Am Heart J 154 2007 221 231
244. Sofi, F., Giusti, B., Marcucci, R., Gori, A.M., Abbate, R., Gensini, G.F., (in press). Cytochrome P450 2 C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: A meta-analysis. Pharmacogenomics J 10.
245. F. Sofi, R. Marcucci, A.M. Gori, B. Giusti, R. Abbate, and G.F. Gensini Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis Thromb Haemost 103 2010 841 848
246. S.R. Steinhubl, P.B. Berger, J.T. Mann III, E.T. Fry, A. DeLago, and C. Wilmer Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial JAMA 288 2002 2411 2420
247. R.F. Storey Clopidogrel in acute coronary syndrome: To genotype or not? Lancet 373 2009 276 278
248. A. Sugidachi, T. Ogawa, A. Kurihara, K. Hagihara, J.A. Jakubowski, and M. Hashimoto The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite J Thromb Haemost 5 2007 1545 1551
249. J.W. Suh, B.K. Koo, S.Y. Zhang, K.W. Park, J.Y. Cho, and I.J. Jang Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel CMAJ 174 2006 1715 1722
250. T. Szanto, A. Schlammadinger, S. Staelens, S.F. De Meyer, K. Freson, and I. Pareyn The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha Thromb Haemost 98 2007 178 185
251. D. Taubert, A. Kastrati, S. Harlfinger, O. Gorchakova, A. Lazar, and N. von Beckerath Pharmacokinetics of clopidogrel after administration of a high loading dose Thromb Haemost 92 2004 311 316
252. D. Taubert, N. von Beckerath, G. Grimberg, A. Lazar, N. Jung, and T. Goeser Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501
253. The CURE Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-elevation N Engl J Med 345 2001 494 502
254. K.A. Tiroch, D. Sibbing, W. Koch, T. Roosen-Runge, J. Mehilli, and A. Schomig Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J 160 2010 506 512
255. C. Transon, T. Leemann, N. Vogt, and P. Dayer In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin Clin Pharmacol Ther 58 1995 412 417
256. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2 C19 681 G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
257. M. Turpeinen, A. Tolonen, J. Uusitalo, J. Jalonen, O. Pelkonen, and K. Laine Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation Clin Pharmacol Ther 77 2005 553 559
258. K. Umemura, T. Furuta, and K. Kondo The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects J Thromb Haemost 6 2008 1439 1441
259. N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schomig, A. Kastrati, and A. Schomig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial Circulation 112 2005 2946 2950
260. N. von Beckerath, O. von Beckerath, W. Koch, M. Eichinger, A. Schomig, and A. Kastrati P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose Blood Coagul Fibrinolysis 16 2005 199 204
261. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
262. L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O.O. Braun, and J.A. Jakubowski Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
263. T.H. Wang, D.L. Bhatt, and E.J. Topol Aspirin and clopidogrel resistance: An emerging clinical entity Eur Heart J 27 2006 647 654
264. G.J. Wang, P. Yang, and H.G. Xie Gene variants in noncoding regions and their possible consequences Pharmacogenomics 7 2006 203 209
265. S.A. Ward, T. Walle, U.K. Walle, G.R. Wilkinson, and R.A. Branch Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities Clin Pharmacol Ther 45 1989 72 79
266. P. Wenaweser, J. Dorffler-Melly, K. Imboden, S. Windecker, M. Togni, and B. Meier Stent thrombosis is associated with an impaired response to antiplatelet therapy J Am Coll Cardiol 45 2005 1748 1752
267. P. Wenaweser, S. Windecker, M. Billinger, S. Cook, M. Togni, and B. Meier Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis Am J Cardiol 99 2007 353 356
268. H. Wienbergen, A.K. Gitt, R. Schiele, C. Juenger, T. Heer, and C. Meisenzahl Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies Am J Cardiol 92 2003 285 288
269. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
270. R. Wolbold, K. Klein, O. Burk, A.K. Nussler, P. Neuhaus, and M. Eichelbaum Sex is a major determinant of CYP3A4 expression in human liver Hepatology 38 2003 978 988
271. H.G. Xie Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects Clin Pharmacol Ther 62 1997 691 692
272. H.G. Xie Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population Life Sci 66 2000 L175 L181
273. H.G. Xie Personalized immunosuppressive therapy in pediatric heart transplantation: Progress, pitfalls and promises Pharmacol Ther 126 2010 146 158
274. H.G. Xie, and F.W. Frueh Pharmacogenomics steps toward personalized medicine Personalzied Med 2 2005 325 337
275. H.G. Xie, S.L. Huang, Z.H. Xu, Z.S. Xiao, N. He, and H.H. Zhou Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population Pharmacogenetics 7 1997 115 119
276. H.G. Xie, and R.B. Kim St John's wort-associated drug interactions: Short-term inhibition and long-term induction? Clin Pharmacol Ther 78 2005 19 24
277. H.G. Xie, R.B. Kim, C.M. Stein, G.R. Wilkinson, and A.J. Wood Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent Br J Clin Pharmacol 48 1999 402 408
278. H.G. Xie, R.B. Kim, A.J. Wood, and C.M. Stein Molecular basis of ethnic differences in drug disposition and response Annu Rev Pharmacol Toxicol 41 2001 815 850
279. H.G. Xie, H.C. Prasad, R.B. Kim, and C.M. Stein CYP2C9 allelic variants: Ethnic distribution and functional significance Adv Drug Deliv Rev 54 2002 1257 1270
280. H.G. Xie, C.M. Stein, R.B. Kim, G.R. Wilkinson, D.A. Flockhart, and A.J. Wood Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world Pharmacogenetics 9 1999 539 549
281. H.G. Xie, A.J. Wood, R.B. Kim, C.M. Stein, and G.R. Wilkinson Genetic variability in CYP3A5 and its possible consequences Pharmacogenomics 5 2004 243 272
282. S.U. Yasuda, L. Zhang, and S.M. Huang The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies Clin Pharmacol Ther 84 2008 417 423
283. A.M. Yousef, T. Arafat, N.R. Bulatova, and R. Al Zumyli Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel J Clin Pharm Ther 33 2008 439 449
284. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
285. A. Zahno, K. Brecht, M. Bodmer, D. Bur, D.A. Tsakiris, and S. Krahenbuhl Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro Br J Pharmacol 161 2010 393 404
286. S. Zhou, C.S. Yung, G.B. Cher, E. Chan, W. Duan, and M. Huang Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Clin Pharmacokinet 44 2005 279 304
287. H.J. Zhu, K.S. Patrick, H.J. Yuan, J.S. Wang, J.L. Donovan, and C.L. DeVane Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: Clinical significance and molecular basis Am J Hum Genet 82 2008 1241 1248